Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: A single center experience of 10 years

Annals of Oncology

Volumn 16, Issue 2, 2005, Pages 206-214

  Au, W Y ^a   Ma, S Y ^a   Chim, C S ^a   Choy, C ^a   Loong, F ^a   Lie, A K W ^a   Lam, C C K ^a   Leung, A Y H ^a   Tse, E ^a   Yau, C C ^a   Liang, R ^a   Kwong, Y L ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Chinese; Mature T cell lymphoma; NK cell lymphoma

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUDARABINE; IFOSFAMIDE; METHOTREXATE; MITOXANTRONE; PREDNISOLONE; PROCARBAZINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; FEMALE; HISTOPATHOLOGY; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; PERIPHERAL T CELL LYMPHOMA; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; SCHOOL CHILD; T CELL LYMPHOMA; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

EID: 20044373438     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi037     Document Type: Review

References (40)

1. Spits H, Lanier LL, Phillips JH. Development of human T and natural killer cells. Blood 1995; 85: 2654-2670.
2. Jaffe E, Ralfkiaer E. Mature T-cell and, NK-cell neoplasms: introduction. In Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): World Health Organization Classification of Tumours. Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press 2001; 191-194.
3. Shih LY, Liang DC. Non-Hodgkin's lymphomas in Asia. Hematol Oncol Clin North Am 1991; 5: 983-1001.
4. Su IJ, Shih LY, Kadin ME et al. Pathologic and immunologic characterization of malignant lymphoma. in Taiwan. Am J Clin Pathol 1985; 84: 715-723.
5. Ng CS, Chan JK, Lo ST, Poon YF. Immunophenotypic analysis of non-Hodgkin's lymphomas in Chinese. A study of 75 cases in Hong Kong. Pathology 1986; 18: 419-425.
6. Ho FC, Loke SL, Hui PK, Todd D. Immunohistological subtypes of non-Hodgkin's lymphoma in Hong Kong Chinese. Pathology 1986; 18: 426-430.
7. Cheng AL, Chen YC, Wang CH et al. Direct comparisons of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades - should peripheral T-cell lymphoma be considered separately? J Clin Oncol 1989; 7: 725-731.
8. Shimoyama M. Peripheral T-cell lymphoma in Japan: recent progress. Ann Oncol 1991; 2 (Suppl 2): 157-162.
9. Nakamura S, Suchi T, Koshikawa T et al. Clinicopathologic study of 212 cases of peripheral T-cell lymphoma among the Japanese. Cancer 1993; 72: 1762-1772.
10. Chuang SS, Lin CN, Li CY. Malignant lymphoma in southern Taiwan according to the revised European-American classification of lymphoid neoplasms. Cancer 2000; 89: 1586-1592.
11. Chan JK, Jaffe E, Ralfkiaer E. Extranodal NK/T-cell lymphoma, nasal type. In Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): World Health Organization Classification of Tumours. Tumours of Haematopoietic and Lymphoid Tissues. Lyon, IARC Press 2001; 204-207.
12. Chim CS, Ma SY, Au WY et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the international prognostic index. Blood 2004; 103: 216-221.
13. Gaal K, Sun NC, Hernandez AM, Arber DA. Sinonasal NK/T-cell lymphomas in the United States. Am J Surg Pathol 2000; 24: 1511-1517.
14. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997; 89: 3909-3918.
15. Tao Q, Ho FC, Loke SL, Srivastava G. Epstein-Barr virus is localized in the tumour cells of nasal lymphomas of NK, T or B cell type. Int J Cancer 1995; 60: 315-320.
16. Chiang AK, Srivastava G, Lau PW, Ho FC. Differences in T-cell-receptor gene rearrangement and transcription in nasal lymphomas of natural killer and T-cell types: implications on cellular origin. Hum Pathol 1996; 27: 701-707.
17. Ku LS, Ko KK. Mycosis fungoides - a retrospective review of 40 cases in Hong Kong Chinese. Int J Dermatol 2004 (in press).
18. Kwong YL, Lam CC, Chan TM. Post-transplantation lymphoproliferative disease of natural killer cell lineage: a clinicopathological and molecular analysis. Br J Haematol 2000; 110: 197-202.
19. Au WY, Ng WM, Choy C, Kwong YL. Aggressive subcutaneous panniculitis-like T-cell lymphoma: complete remission with fludarabine, mitoxantrone and dexamethasone. Br J Dermatol 2000; 143: 408-410.
20. Ma SY, Au WY, Chim CS et al. Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patients. Br J Haematol 2004; 124: 754-761.
21. Kwong YL, Lam CC, Choy C et al. Chronic T-cell lymphoproliferative disease expressing natural killer cell receptors: clinicopathological and molecular features. Cancer Genet Cytogenet 2001; 129: 168-172.
22. Rudiger T, Weisenburger DD, Anderson JR et al. for the Non-Hodgkin's Lymphoma Classification Project. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 2002; 13: 140-149.
23. Kwong YL, Wong KF, Chan LC et al. The spectrum of chronic lymphoproliferative disorders in Chinese people. An analysis of 64 cases. Cancer 1994; 74: 174-181.
24. Ma SY, Ma SY, Au WY et al. Fludarabine, mitoxantrone and dexamethasone in the treatment of indolent B- and T-cell lymphoid malignancies in Chinese patients. Br J Haematol 2004; 124: 754-761.
25. Ho FC, Todd D, Loke SL et al. Clinico-pathological features of malignant lymphomas in 294 Hong Kong Chinese patients. Retrospective study covering an eight-year period. Int J Cancer 1984; 34: 143-148.
26. Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
27. Chan JK, Tsang WY, Ng CS. Clarification of CD3 immunoreactivity in nasal T/natural killer cell lymphomas: the neoplastic cells are often CD3 epsilon+. Blood 1996; 87: 839-841.
28. en Berge RL, Oudejans JJ, Ossenkoppele GJ, Meijer CJ. ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects-a review. J Pathol 2003; 200: 4-15.
29. ten Berge RL, Dukers DF, Oudejans JJ et al. Adverse effects of activated cytotoxic T lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma. Blood 1999; 93: 2688-2696.
30. Falini B, Pileri S, Zinzani PL et al. ALK+ lymphoma: clinicopathological findings and outcome. Blood 1999; 93: 2697-2706.
31. Gascoyne RD, Aoun P, Wu D et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 1999; 93: 3913-3921.
32. Pautier P, Devidas A, Delmer A et al. Angioimmunoblastic-like T-cell non Hodgkin's lymphoma: outcome after chemotherapy in 33 patients and review of the literature. Leuk Lymphoma 1999; 32: 545-552.
33. ten Berge RL, de Bruin PC, Oudejans JJ et al. ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. Histopathology 2003; 43: 462-469.
34. Kwong YL, Chan AC, Liang R et al. CD56+ NK lymphomas: clinicopathological features and prognosis. Br J Haematol 1997; 97: 821-829.
35. Siu LL, Chan JK, Kwong YL. Natural killer cell malignancies: clinicopathologic and molecular features. Histol Histopathol 2002; 17: 539-554.
36. Au WY, Lie AK, Liang R et al. Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value. Ann Oncol 2003; 14: 1673-1676.
37. Melnyk A, Rodriguez A, Pugh WC, Cabannillas F. Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma. Blood 1997; 89: 4514-4520.
38. Gisselbrecht C, Gaulard P, Lepage E et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). Blood 1998; 92: 76-82.
39. ten Berge RL, Meijer CJ, Dukers DF et al. Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood 2002; 99: 4540-4546.
40. Tsuchiya T, Ohshima K, Karube K et al. Th1, Th2, and activated T-cell marker and clinical prognosis in peripheral T-cell lymphoma, unspecified: comparison with AILD, ALCL, lymphoblastic lymphoma, and ATLL. Blood 2004; 103: 236-241.